共 115 条
[1]
Ali S(2019)The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia Oncologist 24 e171-e179
[2]
Dunmore HM(2018)Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia Expert Rev Clin Pharmacol 11 549-559
[3]
Karres D(2011)Genetic abnormalities and challenges in the treatment of acute myeloid leukemia Genes Cancer 2 95-107
[4]
Hay JL(2005)CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance Leukemia 19 176-182
[5]
Salmonsson T(2005)Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 104 1442-1452
[6]
Gisselbrecht C(2012)Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 379 1508-1516
[7]
Sarac SB(2007)High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group Leukemia 21 66-71
[8]
Bjerrum OW(2018)FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia Clin Cancer Res 24 3242-3246
[9]
Hovgaard D(2018)FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia Oncologist 23 1103-1108
[10]
Barbachano Y(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 129 424-447